Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Dosing Time in Female OAB
NCT03251300Phase 4Unknown
- Sponsor
- Far Eastern Memorial Hospital
- Start
- Aug 2017
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mirabegron in overactive bladder syndrome (OAB) (2 arms), sponsored by Far Eastern Memorial Hospital. Primary endpoints: Number of nocturia episodes at 12 weeks and Number of urgency episodes at 12 weeks. Status: unknown.
02
Drugs
mirabegron
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT03251300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251300.